Democratizing Precision Medicine for the Humanity.

Diagnostics

aiGEN BIO is dedicated to enhancing the accessibility and affordability of life-changing medical care by minimizing financial barriers and emphasizing high-quality healthcare services. The integration of artificial intelligence (AI) technologies in clinical applications of Whole Genome Sequencing (cWGS) studies and medical research has made remarkable progress in enhancing diagnostic accuracy and treatment effectiveness.

aiGEN BIO makes substantial investments in cutting-edge technologies, medical equipment, and well-trained healthcare professionals to ensure prompt and efficient diagnosis, treatment, and follow-up for patients. Through continuous research and innovation, aiGEN BIO aims to discover novel and transformative diagnostic tools and therapies that can significantly improve patient outcomes.

The company offers a comprehensive range of diagnostic products that go beyond traditional laboratory testing, providing medical interpretation as well as extensive support to patients and their families. Utilizing their medical informatics platform, “Eratosthenes IV,” which grants access to a diverse repository of biobanked samples and a global clinical network, aiGEN BIO is committed to delivering rapid and actionable diagnostic results to both patients and physicians, particularly for complex diseases and the assessment of risk in asymptomatic individuals.

Artificial Intelligence (AI)

Artificial intelligence (AI) has revolutionized the way healthcare professionals approach precision medicine. By analyzing vast amounts of data using AI technologies, healthcare professionals can extract valuable insights that lead to more accurate diagnoses, personalized treatments, and improved patient outcomes. Here are some of the major areas of impact:

1. Data Analysis and Interpretation: AI algorithms excel at analyzing complex datasets, including genomic data, electronic health records, and medical imaging. Machine learning techniques enable the identification of patterns, correlations, and biomarkers that can guide precise diagnosis and treatment selection.

2. Predictive Modeling and Risk Assessment: AI models can predict disease progression, treatment response, and patient outcomes by integrating various data sources. These models assist in risk assessment, enabling clinicians to tailor interventions and preventive strategies based on an individual’s specific health profile.

3. Drug Discovery and Development: AI algorithms accelerate the drug discovery process by analyzing vast molecular databases, predicting drug-target interactions, and simulating drug effects. This approach expedites the identification of potential therapeutics, leading to more targeted treatments and personalized medicine.

4. Clinical Decision Support Systems: AI-powered clinical decision support systems provide healthcare professionals with real-time guidance and recommendations based on patient data, medical guidelines, and expert knowledge. These systems enhance diagnostic accuracy, treatment planning, and monitoring, ultimately improving patient safety and care quality.

5. Precision Oncology: AI has significantly impacted precision oncology, where tailored treatments are crucial. By analyzing molecular data, AI algorithms can identify genetic mutations and biomarkers associated with cancer subtypes, aiding in targeted therapies and predicting treatment responses.

6. Patient Stratification and Trial Design: AI algorithms can identify patient subgroups with distinct characteristics and treatment responses. This stratification enables more effective clinical trial design, leading to faster drug approvals, reduced trial costs, and improved patient recruitment.

7. Ethical and Regulatory Considerations: The integration of AI in precision medicine raises important ethical and regulatory considerations. Ensuring patient privacy, transparency in algorithmic decision-making, and addressing potential biases are essential to build trust and upholding ethical standards.

AI technologies are transforming healthcare delivery by unlocking new insights and providing personalized, targeted treatments that enhance patient care and outcomes.

Diagnostic Services

1.1. Preventive Clinical Whole Genome Sequencing + Mitochondrial DNA (cWGS + mtDNA) – Asymptomatic individuals with significant clinical-genetic family history.

1.2. Clinical Whole Genome Sequencing + Mitochondrial DNA (DNA (cWGS + mtDNA). – Complex cases, diagnostic odyssey, and therapeutic guidance.

1.3. Identification of clinically actionable variants from genome sequencing of families with congenital diseases.

1.4. Misdiagnosis and Rare Genetic Syndromes (cWGS + mitochondrial DNA/Panels)

1.5. Chromosomal Microarray Testing (CMT).

1.6. NGS PANELS

1.6.1. CARDIOLOGY – CARDIOVASCULAR DISEASES

1.6.2. ONCOLOGY

1.6.3. NEUROLOGY

1.6.4. MASTOLOGY

1.6.5. NEPHROLOGY

1.6.6. METABOLIC DISEASES

1.6.7. IMMUNOLOGY

1.6.8. NEONATOLOGY

1.6.9. RARE DISEASES

1.6.10. VASCULAR DISEASES

1.6.11. OPHTALMOLOGY

1.6.12. OTORHINOLARYNGOLOGY

1.6.13. HEMATOLOGY

1.6.14. DYSMORPHOLOGY

1.6.15. GASTROENTEROLOGY

1.6.16. REPRODUCTIVE MEDICINE

1.7. “Omics” complex tests.